Benjamin Hanfstein

TL;DR: Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.

TL;DR: Treatment optimization is recommended for pts missing these landmarks and early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise consider the use of a second-generation tyrosine kinase inhibitor (TKI).

TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.

TL;DR: It is concluded that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis.

TL;DR: After 10 years, IM continues to be an excellent initial choice for most patients with CML and the deep molecular response rates indicate that most patients are candidates for IM discontinuation.